Fate Therapeutics, Inc. — Net Income by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/99fa1c82-72ed-4a9b-a08b-0041d18f5ec5/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-136.3M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-073699 |
| FY 2024 | $-186.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-033510 |
| FY 2023 | $-160.9M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-020158 |
| FY 2022 | $-281.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005067 |
| FY 2021 | $-212.2M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002293 |
| FY 2020 | $-173.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008086 |
| FY 2019 | $-98.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-008141 |
| FY 2018 | $-66.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006258 |
| FY 2017 | $-43.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004394 |
| FY 2016 | $-33.5M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004614 |
| FY 2015 | $-30.0M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013981 |
| FY 2014 | $-25.9M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-002070 |
| FY 2013 | $-93.5M | 2007-04-27 – 2014-03-31 | evidence 0001104659-14-038138 |
| FY 2012 | $-14.2M | 2012-01-01 – 2012-12-31 | evidence 0001047469-14-002516 |
| FY 2011 | $-13.4M | 2011-01-01 – 2011-12-31 | evidence 0001047469-14-002516 |
| FY 2010 | $-16.2M | 2010-01-01 – 2010-12-31 | evidence 0001047469-14-002516 |
| FY 2009 | $-13.3M | 2009-01-01 – 2009-12-31 | evidence 0001047469-14-002516 |
| FY 2008 | $-7.2M | 2008-01-01 – 2008-12-31 | evidence 0001047469-14-002516 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Fate Therapeutics, Inc. — all facts · Revenue · Operating Income